Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups, Determining Safety, Efficacy and PK of Intravitreous Injections of Pegaptanib Sodium Compared to Sham Injection for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to CRVO
Brief Summary: Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye.

The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK).

This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.


Options:
A: Intervention Type: DRUG; Name: pegaptanib sodium; Assigned to Arm(s): N/A
B: Arm Label: Arm I (paclitaxel and carboplatin); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Other: laboratory biomarker analysis | Arm Label: Arm II (paclitaxel, carboplatin, and bevacizumab); Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: carboplatin, Biological: bevacizumab, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, carboplatin, and bevacizumab) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (paclitaxel and carboplatin), Arm II (paclitaxel, carboplatin, and bevacizumab)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
D: Arm Label: Ranibizumab alone; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab and MMC; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab and MMC | Arm Label: MMC alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: MMC | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab alone | Intervention Type: DRUG; Name: Ranibizumab and MMC; Assigned to Arm(s): Ranibizumab and MMC | Intervention Type: DRUG; Name: MMC; Assigned to Arm(s): MMC alone

Answer: A